“In order to protect the general public, the Food and Drug Administration (FDA) immediately directed Sanofi to SUSPEND the sale/distribution/marketing of Dengvaxia and cause the WITHDRAWAL of Dengvaxia in the market pending compliance with the directives of the FDA,” ang nakasaad sa advisory ng FDA.

“The FDA is closely coordinating with the Department of Health (DOH) for any adverse events/reactions that may be reported by the recipients following their immunization of the Dengvaxia, and will immediately take appropriate measures to protect the public,” turan pa ng FDA sa advisory nito.